Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NP001 in ALS with Systemic Inflammation
NCT02794857Phase 2Completed
- Sponsor
- Neuraltus Pharmaceuticals
- Start
- Aug 2016
- Primary completion
- Dec 2017
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing NP001 with Placebo (2 arms). Primary endpoint: ALS Functional Rating Scale-Revised at 6 months. Started Aug 2016; status: completed.
02
Drugs
sodium chlorite
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02794857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02794857.